Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methylene blue + chlorhexidine gluconate is a combination of two active compounds commonly formulated as a mouthwash, oral rinse, cutaneous solution, or antimicrobial preparation. Methylene blue is a synthetic phenothiazinium dye with antiseptic, bacteriostatic, and broad-spectrum antimicrobial properties, often used for its redox activity and as a photosensitizer in photodynamic therapy, exhibiting antibacterial effects both with and without light activation. Chlorhexidine gluconate is a bisbiguanide antiseptic recognized as the gold standard in oral antimicrobial agents, acting as a broad-spectrum agent effective against Gram-positive and Gram-negative bacteria by disrupting microbial cell membranes. The combination is evaluated as an antiplaque, anti-gingivitis, and wound care agent, with evidence suggesting methylene blue contributes lower cytotoxicity compared to chlorhexidine alone. This combination is under investigation for clinical use in oral health (mouthwash, periodontology), surface and skin disinfection, and possibly for viral decontamination in the oral cavity.[1][3][5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methylene blue + chlorhexidine gluconate.